Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial

Weight Loss

Novo Nordisk Scores Major Court Win, Dutch Judge Halts Compounded Semaglutide Nasal Spray
Novo Nordisk Scores Major Court Win, Dutch Judge Halts Compounded Semaglutide Nasal Spray
Cencora Sees Specialty Growth Continue While GLP-1 Mix Weighs on Margins
Cencora Sees Specialty Growth Continue While GLP-1 Mix Weighs on Margins
Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion
Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion
Cencora Sees Specialty Growth Continue While GLP-1 Mix Weighs on Margins
Cencora Sees Specialty Growth Continue While GLP-1 Mix Weighs on Margins
Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion
Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion
CVS Targets Affordable GLP-1 Access With New Eli Lilly Deal
CVS Targets Affordable GLP-1 Access With New Eli Lilly Deal
Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks
Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks

Weight Loss Recent News

Wegovy Pill in Europe - Novo Nordisk Expands Franchise With First European Approval for Oral Weight Loss Drug
Wegovy Pill in Europe - Novo Nordisk Expands Franchise With First European Approval for Oral Weight Loss Drug
Novo Nordisk wins EU approval for Wegovy pill, the first oral GLP-1 for weight management, backed by OASIS trial data.
Fractyl Health Helps Maintain Weight After Stopping Popular Obesity Drugs, Stock Soars
Fractyl Health Helps Maintain Weight After Stopping Popular Obesity Drugs, Stock Soars
Fractyl Health reported one-year REMAIN-1 data showing Revita reduced weight regain after GLP-1 therapy with favorable safety results.
Why Is Kailera Therapeutics Stock Falling Tuesday?
Why Is Kailera Therapeutics Stock Falling Tuesday?
Kailera Therapeutics oral GLP-1 meets Phase 3 targets for obesity and diabetes. KLRA stock falls 9% on reported GI side effects.
Novo Nordisk Advances Weight-Loss Portfolio With UK Approval Of Wegovy Tablet
Novo Nordisk Advances Weight-Loss Portfolio With UK Approval Of Wegovy Tablet
Novo Nordisk wins U.K. approval for Wegovy pill, offering adults a daily oral weight-loss option backed by Phase 3 trial data.
AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials
AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials
AstraZeneca advances oral GLP-1 elecoglipron to Phase 3 following strong weight loss & diabetes data at ADA 2026. Get the trial details.
Eli Lilly Highlights Weight Loss Benefits For Women Across Menopausal Stages
Eli Lilly Highlights Weight Loss Benefits For Women Across Menopausal Stages
Eli Lilly reports Foundayo delivered significant weight loss across menopausal stages, with up to 14.4% reductions at 72 weeks.
Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss
Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss
Eli Lilly says retatrutide helped obesity trial participants lose up to 28.3% body weight in the Phase 3 TRIUMPH-1 study.
Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report
Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report
Donald Trump disclosed up to $680,000 in Eli Lilly stock purchases as Medicare initiatives advanced GLP-1 drug coverage.
This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst
This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst
William Blair gives Kailera Therapeutics ($KLRA) an Outperform rating. Learn why analysts see a competitive edge in their GLP-1 assets.
Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss
Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss
Eli Lilly data shows patients maintain weight loss with Foundayo or lower-dose Zepbound after switching from injectable therapies.
Novo Nordisk Presents New Wegovy Data Showing Strong Weight Loss, Fat Reduction
Novo Nordisk Presents New Wegovy Data Showing Strong Weight Loss, Fat Reduction
Novo Nordisk said higher-dose Wegovy drove greater weight loss in obesity patients, with most reductions tied to body fat.
WW International Q1 Revenue Beats, But Subscriber Decline, EBITDA Loss Sink Shares
WW International Q1 Revenue Beats, But Subscriber Decline, EBITDA Loss Sink Shares
WW shares drop after the company reports a wider quarterly loss, weaker behavioral subscriber trends and negative adjusted EBITDA.
Eli Lilly Jumps As Earnings Beat Meets FDA Tightening Drug Compounding Rules
Eli Lilly Jumps As Earnings Beat Meets FDA Tightening Drug Compounding Rules
Eli Lilly lifts 2026 outlook after Q1 beat; FDA targets compounded GLP-1 drugs, tightening rules on semaglutide, tirzepatide, liraglutide.
Hims & Hers Positions Itself As Supply Anchor In Hormone Therapy Crunch
Hims & Hers Positions Itself As Supply Anchor In Hormone Therapy Crunch
Hims & Hers expands GLP-1 access, partners with drugmakers, and addresses estrogen patch shortages amid rising menopause care demand.
Novo Nordisk Eyes Approval For Potential First Oral GLP-1 Diabetes Pill In Young Patients
Novo Nordisk Eyes Approval For Potential First Oral GLP-1 Diabetes Pill In Young Patients
Novo Nordisk reports phase 3 data showing oral semaglutide reduced HbA1c in adolescents with type 2 diabetes and was well tolerated.
Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake
Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake
Eli Lilly obesity pill logs 1,390 U.S. scripts in first week, trailing Novo's oral Wegovy as competition in weight-loss drugs intensifies.
Eli Lilly's New Oral Weight Loss Drug Clears Cardiovascular Bar
Eli Lilly's New Oral Weight Loss Drug Clears Cardiovascular Bar
Eli Lilly Foundayo shows cardiovascular safety and stronger A1C, weight reduction, while the FDA flags liver risk, seeks additional data.
GoodRx Rallies As Wegovy HD Rollout Targets Self-Pay Market
GoodRx Rallies As Wegovy HD Rollout Targets Self-Pay Market
GoodRx shares rise as Wegovy HD rollout expands self-pay access, with tiered pricing and mixed technical signals.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved